537 results on '"Pei, York"'
Search Results
2. Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy
3. Real-life use of tolvaptan in ADPKD: a retrospective analysis of a large Canadian cohort
4. Atypical Polycystic Kidney Disease as defined by Imaging
5. Short salsalate administration affects cell proliferation, metabolism, and inflammation in polycystic kidney disease
6. Assessing the Risk of Progression to Kidney Failure in Patients With Autosomal Dominant Polycystic Kidney Disease
7. Urinary epidermal growth factor/monocyte chemotactic peptide 1 ratio as non-invasive predictor of Mayo clinic imaging classes in autosomal dominant polycystic kidney disease
8. The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD
9. Genetics in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
10. Myocardin-Related Transcription Factor Mediates Epithelial Fibrogenesis in Polycystic Kidney Disease
11. Reprogramming of Energy Metabolism in Human PKD1 Polycystic Kidney Disease: A Systems Biology Analysis
12. Advancing Genetic Testing in Kidney Diseases: Report From a National Kidney Foundation Working Group
13. Type IV Collagen Variants in CKD: Performance of Computational Predictions for Identifying Pathogenic Variants
14. Navigating the Global Economic Landscape of Dialysis: A Summary of Expert Opinions from The 4th International Congress of Chinese Nephrologists.
15. Global microRNA profiling in human urinary exosomes reveals novel disease biomarkers and cellular pathways for autosomal dominant polycystic kidney disease
16. Connectivity mapping of a chronic kidney disease progression signature identified lysine deacetylases as novel therapeutic targets
17. Myocardin-related transcription factor drives epithelial fibrogenesis in polycystic kidney disease
18. Imaging-Based Diagnosis of Autosomal Dominant Polycystic Kidney Disease
19. LAMA2 and LOXL4 are candidate FSGS genes
20. Foam Sclerotherapy for Cyst Volume Reduction in Autosomal Dominant Polycystic Kidney Disease: A Prospective Cohort Study
21. ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption
22. PKHD1 Protein Encoded by the Gene for Autosomal Recessive Polycystic Kidney Disease Associates with Basal Bodies and Primary Cilia in Renal Epithelial Cells
23. Molecular Diagnosis of Autosomal Dominant Polycystic Kidney Disease
24. Digenic Inheritance of Extracellular Matrix Mutations in a Family with FSGS: PUB140
25. #5783 REAL-LIFE USE OF TOLVAPTAN IN ADPKD: A RETROSPECTIVE ANALYSIS OF A LARGE CANADIAN COHORT
26. Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial
27. Total Kidney Volume Measurements in ADPKD by 3D and Ellipsoid Ultrasound in Comparison with Magnetic Resonance Imaging
28. Autosomal dominant polycystic kidney disease management
29. Prognostic Performance of Kidney Volume Measurement for Polycystic Kidney Disease: A Comparative Study of Ellipsoid vs. Manual Segmentation
30. Preclinical evaluation of tolvaptan and salsalate combination therapy in a Pkd1-mouse model
31. Autosomal Dominant Polycystic Kidney Disease: Role of Imaging in Diagnosis and Management
32. Characterization of the Intrarenal Renin-Angiotensin System in Experimental Alport Syndrome
33. Isolated polycystic liver disease genes define effectors of polycystin-1 function
34. Methodological issues in clinical trials of polycystic kidney disease: a focused review
35. Shared pathobiology identifies AMPK as a therapeutic target for obesity and autosomal dominant polycystic kidney disease
36. Genetics in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
37. Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease
38. Polycystic Kidney Disease without an Apparent Family History
39. Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency
40. Urinary epidermal growth factor/monocyte chemotactic peptide 1 ratio as non-invasive predictor of Mayo clinic imaging classes in autosomal dominant polycystic kidney disease.
41. Safety of High-Dose 3% Sodium Tetradecyl Sulfate for Sclerotherapy of Renal Cysts in Patients with Autosomal Dominant Polycystic Kidney Disease
42. Atypical Polycystic Kidney Disease by Imaging
43. Signal transducer and activator of transcription-6 (STAT6) inhibition suppresses renal cyst growth in polycystic kidney disease
44. Renal Cell Carcinoma in the Native and Allograft Kidneys of Renal Transplant Recipients
45. Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease
46. Autosomal dominant polycystic kidney disease
47. Diagnosis and Screening of Autosomal Dominant Polycystic Kidney Disease
48. Diagnosis of Autosomal-Dominant Polycystic Kidney Disease: An Integrated Approach
49. GWAS defines pathogenic signaling pathways and prioritizes drug targets for IgA nephropathy
50. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.